Business Description
Novo Nordisk AS
ISIN : US6701002056
Share Class Description:
NVO: ADRTotal Employee Number:
69,500Compare
Compare
Traded in other countries / regions
NOVO B.DenmarkNVO.USA0QIU.UKNOV.GermanyNVON.CanadaN1VO34.BrazilNNO2.AustriaNVON.MexicoNVO.PolandNOV.Bulgaria IPO Date
1981-04-30Description
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.36 | |||||
Debt-to-Equity | 0.72 | |||||
Debt-to-EBITDA | 0.81 | |||||
Interest Coverage | 58.85 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.4 | |||||
Beneish M-Score | -2.23 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.3 | |||||
3-Year EBITDA Growth Rate | 27.8 | |||||
3-Year EPS without NRI Growth Rate | 25.8 | |||||
3-Year FCF Growth Rate | -22.7 | |||||
3-Year Book Growth Rate | 33 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.87 | |||||
9-Day RSI | 74.64 | |||||
14-Day RSI | 70.5 | |||||
3-1 Month Momentum % | 6.4 | |||||
6-1 Month Momentum % | -30.13 | |||||
12-1 Month Momentum % | -35.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.79 | |||||
Quick Ratio | 0.56 | |||||
Cash Ratio | 0.1 | |||||
Days Inventory | 290.77 | |||||
Days Sales Outstanding | 81.92 | |||||
Days Payable | 440.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.45 | |||||
Dividend Payout Ratio | 0.5 | |||||
3-Year Dividend Growth Rate | 27.8 | |||||
Forward Dividend Yield % | 3.45 | |||||
5-Year Yield-on-Cost % | 10.03 | |||||
3-Year Average Share Buyback Ratio | 0.4 | |||||
Shareholder Yield % | 1.39 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.85 | |||||
Operating Margin % | 45.3 | |||||
Net Margin % | 37.21 | |||||
EBITDA Margin % | 55.38 | |||||
FCF Margin % | 9.36 | |||||
OCF Margin % | 36.14 | |||||
ROE % | 69.8 | |||||
ROA % | 23.58 | |||||
ROIC % | 24.26 | |||||
3-Year ROIIC % | 20.71 | |||||
ROC (Joel Greenblatt) % | 82 | |||||
ROCE % | 54.49 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 9 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.08 | |||||
Forward PE Ratio | 15.33 | |||||
PE Ratio without NRI | 14.3 | |||||
Shiller PE Ratio | 22.78 | |||||
Price-to-Owner-Earnings | 11.67 | |||||
PEG Ratio | 0.55 | |||||
PS Ratio | 4.56 | |||||
PB Ratio | 7.35 | |||||
Price-to-Tangible-Book | 20.43 | |||||
Price-to-Free-Cash-Flow | 48.39 | |||||
Price-to-Operating-Cash-Flow | 12.64 | |||||
EV-to-EBIT | 9.93 | |||||
EV-to-Forward-EBIT | 12.48 | |||||
EV-to-EBITDA | 8.74 | |||||
EV-to-Forward-EBITDA | 10.89 | |||||
EV-to-Revenue | 4.84 | |||||
EV-to-Forward-Revenue | 5.59 | |||||
EV-to-FCF | 51.66 | |||||
Price-to-GF-Value | 0.37 | |||||
Price-to-Projected-FCF | 1.61 | |||||
Price-to-DCF (Earnings Based) | 0.57 | |||||
Price-to-DCF (FCF Based) | 3.08 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.58 | |||||
Price-to-Graham-Number | 3.63 | |||||
Earnings Yield (Greenblatt) % | 10.07 | |||||
FCF Yield % | 2.1 | |||||
Forward Rate of Return (Yacktman) % | 23.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:NVO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novo Nordisk AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 51,057.107 | ||
| EPS (TTM) ($) | 4.263 | ||
| Beta | 0.9823 | ||
| 3-Year Sharpe Ratio | -0.26 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 62.18 | ||
| 14-Day RSI | 70.5 | ||
| 14-Day ATR ($) | 1.310012 | ||
| 20-Day SMA ($) | 48.2575 | ||
| 12-1 Month Momentum % | -35.04 | ||
| 52-Week Range ($) | 35.12 - 71.795 | ||
| Shares Outstanding (Mil) | 4,423.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novo Nordisk AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novo Nordisk AS Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 | In 110 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 110 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 | In 19 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 19 days | ||
| First quarter earnings conference call for 2026 | 2026-05-06 13:00 | 44.87 (+0.77%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 44.87 (+0.77%) | ||
| USD 1.217376 Cash Dividend | 2026-03-30 | 36.04 (-0.74%) | ||
| General meeting for 2026 | 2026-03-26 14:00 | 36.33 (-2.21%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-04 07:00 | 50.30 (-13.80%) | ||
| Annual report for 2025 | 2026-02-04 | 50.30 (-13.80%) |
Show
Entries
Novo Nordisk AS Frequently Asked Questions
What is Novo Nordisk AS(NVO)'s stock price today?
The current price of NVO is $51.48. The 52 week high of NVO is $71.80 and 52 week low is $35.12.
When is next earnings date of Novo Nordisk AS(NVO)?
The next earnings date of Novo Nordisk AS(NVO) is 2026-08-05.
Does Novo Nordisk AS(NVO) pay dividends? If so, how much?
The Dividend Yield %  of Novo Nordisk AS(NVO) is 3.45% (As of Today), Highest Dividend Payout Ratio of Novo Nordisk AS(NVO) was 0.62. The lowest was 0.39. And the median was 0.46. The  Forward Dividend Yield % of Novo Nordisk AS(NVO) is 3.45%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:NVO
Press Release
Articles on Novo Nordisk AS
Headlines
See More- 1
Jul 15, 2026
Novo wins EU nod for Wegovy pill and higher-dose Wegovy in single-dose pen
Seeking Alpha • 11:53am
Eli Lilly’s obesity pill is said to trail Novo’s even three months after launch
Seeking Alpha • 8:28am
Jul 07, 2026
Kailera falls after late-stage trial data for oral GLP-1 candidate
Seeking Alpha • 10:41am
Jul 02, 2026
Novo reportedly seeking discounts from suppliers to cut costs
Seeking Alpha • 8:05am
Jul 01, 2026
Medicare's GLP-1 Bridge and what's next for biotech
Seeking Alpha • 10:55am
Jun 26, 2026
Medicare GLP-1 Bridge: What to expect
Seeking Alpha • 9:11am
Jun 17, 2026
Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models
Benzinga • 12:57pm
Midday Need to Know: Retail sales surge, VIX drops & more
Seeking Alpha • 11:03am
Novo to soon follow Lilly in seeking Chinese nod for weight-loss pill
Seeking Alpha • 10:24am
FDA renews crackdown on GLP-1 compounders
Seeking Alpha • 6:13am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers